Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2020

In 2020, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 18.59% of shares outstanding on 15 Jan 2020 to 15.43% on 31 Dec 2020, a change of -3.16 percentage points. The year's high was 25.00% on 15 Jul 2020 and its low 15.43% on 31 Dec 2020, averaging 19.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 33.02 days on 15 Oct 2020. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2020

2020 in figures

Start of year
18.59% (15 Jan 2020)
End of year
15.43% (31 Dec 2020)
Change
-3.16 pp
High
25.00% (15 Jul 2020)
Low
15.43% (31 Dec 2020)
Average
19.10%
Highest days to cover
33.02 (15 Oct 2020)
SEC filings marked
8

Every report in 2020

Atara Biotherapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202018.59%14.72
31 Jan 202017.61%15.76
14 Feb 202017.21%24.41
28 Feb 202018.14%13.9510-K filed, results (8-K)
13 Mar 202018.00%16.65
31 Mar 202018.19%11.81
15 Apr 202018.90%12.65
30 Apr 202020.32%9.81
15 May 202021.30%13.6810-Q filed, results (8-K)
29 May 202020.13%3.35
15 Jun 202019.88%10.33
30 Jun 202023.00%6.91
15 Jul 202025.00%12.43
31 Jul 202018.99%23.68
14 Aug 202019.66%26.2910-Q filed, results (8-K)
31 Aug 202020.54%21.72
15 Sep 202018.46%14.06
30 Sep 202019.07%14.44
15 Oct 202020.78%33.02
30 Oct 202019.71%26.94
13 Nov 202017.67%16.8110-Q filed, results (8-K)
30 Nov 202015.88%14.92
15 Dec 202016.03%9.85
31 Dec 202015.43%14.70

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.